Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC - PubMed (original) (raw)
Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC
Rahul Nahar et al. Blood. 2011.
Abstract
Initial cell surface expression of the pre-B cell receptor induces proliferation. After 2 to 5 divisions, however, large pre-BII (Fraction C') cells exit cell cycle to become resting, small pre-BII cells (Fraction D). The mechanism by which pre-BII cells exit cell cycle, however, is currently unclear. The checkpoint at the Fraction C'-D transition is critical for immunoglobulin light chain gene recombination and to prevent malignant transformation into acute lymphoblastic leukemia. Here we demonstrate that inducible activation of pre-B cell receptor signaling induces cell-cycle exit through up-regulation of the transcriptional repressor BCL6. Inducible activation of BCL6 downstream of the pre-B cell receptor results in transcriptional repression of MYC and CCND2. Hence, pre-B cell receptor-mediated activation of BCL6 limits pre-B cell proliferation and induces cellular quiescence at the small pre-BII (Fraction D) stage.
Figures
Figure 1
Pre-BCR signaling and Ikaros up-regulate BCL6 in normal and leukemic pre-B cells. _Ighm_−/− pro-B cells and _Blnk_−/− pre-BII cells were transformed with BCR-ABL1 and pre-BCR signaling was reconstituted by retroviral expression of BLNK-GFP, CD8/μ-chain or GFP and CD8 empty vectors. BCL6 mRNA levels were measured by quantitative RT-PCR in (A; n = 2) and protein levels were determined by Western blot in (B; n = 2) using β-actin as loading control. IL-7–dependent pre-B cells from Rag2−/− tTA/μ-chain-transgenic mice were cultured in the presence of tetracycline, removal of which induced activation of transgenic μ-chain expression under endogenous transcriptional control elements. Inducible differentiation was verified by flow cytometry (supplemental Figure 2) and BCL6 and MYC protein levels were measured by Western blot (C; n = 2). Normal IL-7–dependent pre-B cells were transduced with a constitutively active (CA) mutant of FoxO1 or an empty vector (transduction efficiency shown in supplemental Figure 1). After inducible activation with 4-hydroxy-tamoxifen (4-OHT), cells were subjected to Western blot analysis for BCL6 and β-actin as loading control (D; n = 2). Likewise, normal IL-7–dependent pre-B cells from Ptenfl/fl mice (supplemental Table 4) were transduced with 4-OHT–inducible Cre-ERT2 or an ERT2 empty vector control and subjected to antibiotic selection. Cre-mediated deletion of Pten and BCL6-up-regulation on IL-7 withdrawal was studied by Western blot using β-actin as loading control (E; n = 2). Pre-B ALL cells from Bcl6+/+ bone marrow were transduced with retroviral expression vectors for BCL6-GFP or a GFP empty vector control. The relative change of the percentage of GFP+ cells over time was measured by flow cytometry (F; n = 2). The cell-cycle profile of transduced cells was measured by BrdU incorporation and flow cytometry (G; n = 2) with statistical analysis (H). Pre-B ALL cells transduced with BCL6-GFP or GFP alone were sorted for GFP and transplanted into sublethally irradiated NOD/SCID mice via tail vein injection (3 mice per group). Spleens of recipient mice and their weight (right) are shown (I).
Figure 2
Pre-B cell receptor–mediated up-regulation of BCL6 inhibits proliferation by transcriptional repression of Myc. Pre-B ALL cells from Bcl6+/+ and _Bcl6_−/− bone marrow were transduced with retroviral expression vectors for CD8/μ-chain or CD8 alone. The relative change of the percentage of CD8+ cells over time was measured by flow cytometry (A; n = 3). To identify BCL6-target genes, ChIP-on-chip analysis was performed for 3 human BCR-ABL1 pre-B ALL cell lines (BV173, Tom1, Nalm1) and 2 human diffuse large B-cell lymphoma cell lines (OCI-Ly1 and OCI-Ly7) as positive controls. High expression levels of BCL6 were induced by treatment of BCR-ABL1 pre-B ALL cell lines with 10μM STI571 for 24 hours (STI571). Recruitment to CCND2 and MYC (see supplemental Figure 3) promoters are shown and to the HPRT promoter as a negative control. The ChIP-on-chip data for Myc in Nalm1 cells is also published in Duy et al. (B) BCR-ABL1 pre-B ALL cells were transduced with 4-hydroxy-tamoxifen (4-OHT)–inducible vectors for BCL6-ERT2 and ERT2 empty vector control. Myc mRNA (C; n = 2) and protein (D; n = 2) levels on 4-OHT induction were measured by quantitative RT-PCR and Western blot, respectively. Induction of BCL6 also resulted in up-regulation of Cdkn1b (p27) protein levels (D). Overexpression of Myc was sufficient to partially rescue BLNK/BCL6-mediated inhibition of proliferation (E): _Blnk_−/− BCR-ABL1 pre-B ALL cells were transduced with Myc-Puro or a Puro-empty vector control and subjected to antibiotic selection. Subsequently, pre-BCR signaling was reconstituted by retroviral expression of BLNK-GFP or a GFP empty vector control and proliferation of the Myc-Puro versus Puro-transduced cells was measured as relative change of the percentage of BLNK-GFP+ or GFP+ cells (E; n = 2).
Similar articles
- BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint.
Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, Carroll WL, Willman CL, Hall AG, Igarashi K, Melnick A, Müschen M. Swaminathan S, et al. Nat Med. 2013 Aug;19(8):1014-22. doi: 10.1038/nm.3247. Epub 2013 Jul 14. Nat Med. 2013. PMID: 23852341 Free PMC article. - BCL6 is critical for the development of a diverse primary B cell repertoire.
Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, Jumaa H, Koeffler HP, de Alborán IM, Melnick AM, Ye BH, Müschen M. Duy C, et al. J Exp Med. 2010 Jun 7;207(6):1209-21. doi: 10.1084/jem.20091299. Epub 2010 May 24. J Exp Med. 2010. PMID: 20498019 Free PMC article. - BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint.
Swaminathan S, Duy C, Müschen M. Swaminathan S, et al. Trends Immunol. 2014 Mar;35(3):131-7. doi: 10.1016/j.it.2013.11.002. Epub 2013 Dec 10. Trends Immunol. 2014. PMID: 24332591 Free PMC article. Review. - ZFP521 contributes to pre-B-cell lymphomagenesis through modulation of the pre-B-cell receptor signaling pathway.
Hiratsuka T, Takei Y, Ohmori R, Imai Y, Ozeki M, Tamaki K, Haga H, Nakamura T, Tsuruyama T. Hiratsuka T, et al. Oncogene. 2016 Jun 23;35(25):3227-38. doi: 10.1038/onc.2015.385. Epub 2015 Nov 2. Oncogene. 2016. PMID: 26522721 - Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.
Müschen M. Müschen M. Blood. 2015 Jun 11;125(24):3688-93. doi: 10.1182/blood-2015-01-567842. Epub 2015 Apr 15. Blood. 2015. PMID: 25878119 Free PMC article. Review.
Cited by
- The F-box E3 ligase protein FBXO11 regulates EBNA3C-associated degradation of BCL6.
Sun K, Bose D, Singh RK, Pei Y, Robertson ES. Sun K, et al. J Virol. 2024 Jul 23;98(7):e0054824. doi: 10.1128/jvi.00548-24. Epub 2024 Jun 12. J Virol. 2024. PMID: 38864622 Free PMC article. - Activation-induced deaminase expression defines mature B cell lymphoma in the mouse.
Gómez-Escolar C, Marina-Zárate E, Ramiro AR. Gómez-Escolar C, et al. Front Immunol. 2023 Sep 21;14:1268930. doi: 10.3389/fimmu.2023.1268930. eCollection 2023. Front Immunol. 2023. PMID: 37809061 Free PMC article. - Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.
Safa FM, Rasmussen T, Fontan L, Xia M, Melnick A, Wiestner A, Lobelle-Rich P, Burger JA, Mouawad Y, Safah H, Flemington EK, Saba NS. Safa FM, et al. Haematologica. 2024 May 1;109(5):1348-1358. doi: 10.3324/haematol.2023.283178. Haematologica. 2024. PMID: 37767562 Free PMC article. - ARID5B regulates fatty acid metabolism and proliferation at the Pre-B cell stage during B cell development.
Chalise JP, Ehsani A, Lemecha M, Hung YW, Zhang G, Larson GP, Itakura K. Chalise JP, et al. Front Immunol. 2023 Jul 7;14:1170475. doi: 10.3389/fimmu.2023.1170475. eCollection 2023. Front Immunol. 2023. PMID: 37483604 Free PMC article. - The discrete roles of individual FOXO transcription factor family members in B-cell malignancies.
Lees J, Hay J, Moles MW, Michie AM. Lees J, et al. Front Immunol. 2023 May 18;14:1179101. doi: 10.3389/fimmu.2023.1179101. eCollection 2023. Front Immunol. 2023. PMID: 37275916 Free PMC article. Review.
References
- Decker DJ, Boyle NE, Koziol JA, Klinman NR. The expression of the Ig H chain repertoire in developing bone marrow B lineage cells. J Immunol. 1991;146(1):350–361. - PubMed
- Jumaa H, Bossaller L, Portugal K, et al. Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia. Nature. 2003;423(6938):452–456. - PubMed
- Flemming A, Brummer T, Reth M, Jumaa H. The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nat Immunol. 2003;4(1):38–43. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01CA104348/CA/NCI NIH HHS/United States
- R01 HL095120/HL/NHLBI NIH HHS/United States
- R21CA152497/CA/NCI NIH HHS/United States
- R01 CA157644/CA/NCI NIH HHS/United States
- R01 CA104348/CA/NCI NIH HHS/United States
- R01CA139032/CA/NCI NIH HHS/United States
- R01 CA137060/CA/NCI NIH HHS/United States
- R21 CA152497/CA/NCI NIH HHS/United States
- R01CA085573/CA/NCI NIH HHS/United States
- R01CA137060/CA/NCI NIH HHS/United States
- R01 CA085573/CA/NCI NIH HHS/United States
- R01 CA139032/CA/NCI NIH HHS/United States
- R01CA157644/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Molecular Biology Databases